Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S ADR (NY: NVO )

122.75 -1.78 (-1.43%)
Official Closing Price Updated: 7:00 PM EDT, Apr 18, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,841,038
Open 123.30
Bid (Size) 122.00 (3)
Ask (Size) 124.70 (1)
Prev. Close 124.53
Today's Range 122.51 - 124.09
52wk Range 75.56 - 138.28
Shares Outstanding N/A
Dividend Yield 1.44%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
German Authority Gives Go Ahead To Novo Nordisk's Small Bolt On Acquisition As Danish Firm Seeks To Build Heart Drugs Pipeline
Novo Nordisk's acquisition of Cardior Pharmaceuticals clears regulatory hurdles, advancing cardiovascular treatment development with CDR132L. Learn about the promising phase 2 trials and strategic... 
Via Benzinga
Patients Find Weight Loss Drug Zepbound A Game Changer, But Makers See Production Delay Until 2025
Facing a shortage, GLP-1 weight loss drugs by Eli Lilly & Novo Nordisk struggle to meet demand. Learn about supply issues and efforts to address them, impacting availability till 2025. 
Via Benzinga

Performance

YTD
+20.21%
+20.21%
1 Month
-6.56%
-6.56%
3 Month
+14.13%
+14.13%
6 Month
+25.69%
+25.69%
1 Year
+48.76%
+48.76%

More News

Read More
How The Weight-Loss Bonanza Prompted A ResMed Sell-Off — But Could Soon Drive Shares Higher
Via Investor's Business Daily
Why Eli Lilly Stock Beat the Market Today While ResMed and AdaptHealth Sank
Via The Motley Fool
Powell And The Great Indecision
Via Talk Markets
Topics Economy
Exposures Economy Interest Rates
If You Invested $1000 In This Stock 5 Years Ago, You Would Have $5,200 Today
Via Benzinga
These 3 Biotech Stocks Are Up 269% in 2024. Is There More to Come?
Via InvestorPlace
Buyback Bonanza: The Top 7 ETFs to Profit From Corporate Cash Splurges
Via InvestorPlace
Topics ETFs
Healthcare Stocks Are Lagging With Big Earnings Weeks Ahead
Via Talk Markets
3 Pharma Stocks That Are Money-Printing Machines in 2024
Via InvestorPlace
Topics Economy
Exposures Economy
Novo Nordisk and Ginkgo Bioworks Are Teaming Up. Here's Why That's Bullish for Both Stocks.
Via The Motley Fool
Better Buy: Bristol Myers Squibb or the Vanguard S&P 500 ETF?
Via The Motley Fool
Topics Stocks
Exposures US Equities
Better Growth Play: Merck or The Vanguard Growth Index Fund?
Via The Motley Fool
Novo Nordisk Arms Wegovy to Be a Triple Threat
Via MarketBeat
NYSE:NVO is showing good growth, while it is not too expensive.
Via Chartmill
Viking Therapeutics: Strong Results In Obesity
Via Talk Markets
Nvidia Leads 5 Stocks Near Buy Points As S&P 500 Tests Key Level
Via Investor's Business Daily
Topics Artificial Intelligence Stocks
Exposures Artificial Intelligence US Equities
Novo Nordisk's Dominance In Obesity & Diabetes Drug Market Backed by Strong Pipeline: Analyst Gives Outperform Rating
Via Benzinga
Eli Lilly Suffers Legal Loss For Its Popular Weight Loss/Diabetes Drug In Lawsuit Against Florida Compounding Pharmacy
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
Novo Nordisk/Eli Lilly's Weight Loss Drugs Does Not Cause Suicidal Behaviors - After FDA, European Medicines Agency Says
Via Benzinga
Exposures Product Safety
Why Wall Street Got Even More Excited About The Glucose Monitor — And How Dexcom, Abbott Labs Stand To Benefit
Via Investor's Business Daily
7 A-Rated Aggressive Biotech Stocks to Bet On in 2024
Via InvestorPlace
Shed the Fat, Gain the Profits: 3 Weight-Loss Stocks to Own Until 2027
Via InvestorPlace
What's Going On With Ginkgo Bioworks Stock?
Via Benzinga
All-Time High Flyers: 7 Stocks to Buy as the Market Peaks
Via InvestorPlace
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.